Revenue remains non-existent in most periods, with the company reporting zero revenue in 2026Q1 while sustaining a $79.8 million operating loss.
| Sales/Revenue | 0 | 15M | 0 | 6.85M | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | -100% | - | - | - | - |
| Cost of Goods Sold | 238.6K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -238.6K | 15M | 0 | 6.85M | 0 | 0 | 0 |
| Gross Margin % | - | 100% | - | 100% | - | - | - |
| Gross Profit Growth % | - | - | -100% | - | - | - | - |
| Operating Expenses | 256.69M | 222.69M | 201.06M | 178.14M | 212.26M | 374.87M | 10.44M |
| OpEx % of Revenue | - | 1484.61% | - | 2599.39% | - | - | - |
| Selling, General & Admin | 58.02M | 50.47M | 50.81M | 53.73M | 55.2M | 43.01M | 1.14M |
| SG&A % of Revenue | - | 336.45% | - | 784.05% | - | - | - |
| Research & Development | 198.67M | 172.22M | 150.24M | 124.41M | 155.08M | 96.32M | 9.3M |
| R&D % of Revenue | - | 1148.16% | - | 1815.34% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 1.98M | 235.54M | 0 |
| Operating Income | -256.69M | -207.69M | -201.06M | -171.28M | -212.26M | -374.87M | -10.44M |
| Operating Margin % | - | -1384.61% | - | -2499.39% | - | - | - |
| Operating Income Growth % | - | -3.3% | -17.38% | 19.31% | 43.38% | -3490.68% | - |
| EBITDA | -256.67M | -207.69M | -200.11M | -170.47M | -212.13M | -374.83M | -10.29M |
| EBITDA Margin % | - | -1384.61% | - | -2487.57% | - | - | - |
| EBITDA Growth % | -31.74% | -3.79% | -17.39% | 19.64% | 43.41% | -3544.46% | - |
| D&A (Non-Cash Add-back) | 21.6K | 0 | 942K | 810K | 131K | 34K | 0 |
| EBIT | -265.47M | -207.69M | -222.82M | -166.24M | -209.68M | -139.33M | -10.29M |
| Net Interest Income | 6.46M | 9.07M | 3.93M | 570K | -7.03M | -2.55M | -378K |
| Interest Income | 17.77M | 20.53M | 14.02M | 10.48M | 244K | 0 | 0 |
| Interest Expense | 11.31M | 11.46M | 10.09M | 9.91M | 7.28M | 2.55M | 378K |
| Other Income/Expense | 7.32M | 11.98M | -31.86M | -4.86M | -4.69M | -6.92M | -223K |
| Pretax Income | -249.37M | -195.71M | -232.91M | -176.14M | -216.95M | -381.79M | -10.66M |
| Pretax Margin % | - | -1304.75% | - | -2570.28% | - | - | - |
| Income Tax | 1.27M | 1.82M | 2.84M | -25.06M | -747K | 114K | 0 |
| Effective Tax Rate % | -0.51% | -0.93% | -1.22% | 14.22% | 0.34% | -0.03% | 0% |
| Net Income | -250.64M | -197.53M | -235.76M | -151.09M | -216.21M | -381.9M | -10.66M |
| Net Margin % | - | -1316.88% | - | -2204.65% | - | - | - |
| Net Income Growth % | -11.97% | 16.21% | -56.04% | 30.12% | 43.39% | -3481.54% | - |
| Net Income (Continuing) | -250.64M | -197.53M | -235.76M | -151.09M | -216.21M | -381.9M | -10.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.63 | -1.46 | -2.06 | -1.57 | -2.31 | -4.24 | -0.08 |
| EPS Growth % | 1.66% | 29.13% | -31.21% | 32.03% | 45.52% | -5356.89% | - |
| EPS (Basic) | - | -1.46 | -2.06 | -1.57 | -2.31 | -4.24 | -0.08 |
| Diluted Shares Outstanding | 153.55M | 135.72M | 114.47M | 96.18M | 93.4M | 89.99M | 70.89M |
| Basic Shares Outstanding | 153.55M | 135.72M | 114.47M | 96.18M | 93.4M | 89.99M | 70.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical trial funding shortfall
As indicated by historical financial filings, Centessa’s revenue remains entirely event-driven and non-recurring, with the company reporting zero revenue in eight of the last ten quarters, underscoring the absence of a commercial-stage product to support its ongoing research and development activities and long-term operational sustainability.
The sporadic nature of the $15 million in revenue recorded in 2025Q1 suggests that inflows are tied to milestone payments rather than consistent product sales. Investors should interpret this lack of top-line growth as a signal that the company remains entirely dependent on external capital to fund its pipeline.
Based on reported income statements, Centessa’s cost structure is dominated by research and development expenses, which reached a peak of $60.9 million in 2024Q4, reflecting the high capital intensity required to advance its clinical-stage assets through complex Phase III registrational trials and regulatory hurdles.
The company’s expense discipline appears focused on prioritizing high-conviction assets, yet the sheer scale of R&D spending relative to the lack of revenue creates a persistent operating deficit. This cost structure necessitates constant monitoring of the company's ability to manage its burn rate while maintaining its clinical momentum.
According to recent financial disclosures, Centessa consistently records significant stock-based compensation, with quarterly figures frequently exceeding $7 million, which effectively dilutes existing shareholders while providing a non-cash mechanism to manage the company's substantial operating losses and retain specialized talent in a competitive biotechnology labor market.
While stock-based compensation is a standard industry practice, the consistent magnitude of these charges relative to the company's net losses warrants careful investigation by investors. It suggests that the true economic cost of operations is higher than the reported net income figures might otherwise imply.
As reported in financial statements, the company’s operating losses have consistently outpaced its cash inflows, with the most recent quarterly operating loss of $79.8 million highlighting a precarious financial position that may necessitate dilutive equity financing to sustain its current clinical development trajectory and operational requirements.
The disparity between the company's cash reserves and its quarterly burn rate suggests that the current financial model is unsustainable without a strategic partnership or capital infusion. Investors should consider the risk that the company may be forced to raise capital at unfavorable terms if clinical milestones are delayed.
Quick answers to the most common questions about buying CNTA stock.
For fiscal year 2025, Centessa Pharmaceuticals plc (CNTA) reported total revenue of $15.0M.
Centessa Pharmaceuticals plc (CNTA) reported a net loss of $197.5M for the fiscal year ending 2025.
Centessa Pharmaceuticals plc (CNTA) reported an operating income of $-207.7M, resulting in an operating profit margin of -1384.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Centessa Pharmaceuticals plc (CNTA) generated $15.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.